Cartilago leverages regenerative medicine to develop disease-modifying chondroprotective technologies to combat osteoarthritis and related conditions
Cartilago leverages regenerative medicine to develop disease-modifying chondroprotective technologies to combat osteoarthritis and related conditions. The company directly addresses the underlying disease pathology to provide not only symptomatic relief but also to inhibit the typical natural progression of the disease. Technologies are being adapted to tackle additional indications, including anti-aging solutions, wound care, and anti-metastatic therapies in cancer.